LobbyingPharmaceutical Research Manufacturers of America lobbying by quarter
Pharmaceutical Research Manufacturers of America's latest lobbying report covers Q2 2026, at $220K. The four quarters Q4 2025–Q3 2026 total $840K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Copyright/Patent/Trademark.
Pharmaceutical Research Manufacturers of America
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $840K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $100K | 2 |
| Q1 2023 | $140K | 2 |
| Q2 2023 | $140K | 2 |
| Q3 2023 | $170K | 2 |
| Q4 2023 | $180K | 2 |
| Q1 2024 | $190K | 2 |
| Q2 2024 | $300K | 2 |
| Q3 2024 | $290K | 2 |
| Q4 2024 | $200K | 2 |
| Q1 2025 | $420K | 2 |
| Q2 2025 | $220K | 2 |
| Q3 2025 | $130K | 2 |
| Q4 2025 | $170K | 2 |
| Q1 2026 | $450K | 2 |
| Q2 2026 | $220K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$1.7M · 24 reports
- Copyright, patent and trademark$1.7M · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE6 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Covington & Burling | $3.3M | 15 quarters |
| Hart Health Strategies | $0 | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SUSAN RAMTHUN | Senator Bill Frist | Q4 2024 |
| TIMOTHY YEHL | Congressman Frank Pallone; Senator Frank Lautenberg | Q4 2024 |
| VICKI HART | Senator Bob Dole; Senator Trent Lott | Q4 2024 |
| JUDITH GORSUCH | Senator Mike Enzi | Q2 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Hart Health Strategies | Under $5,000 |
| 07/20for Q2 | Covington & Burling | $220K |
| 04/20for Q1 | Covington & Burling | $450K |
| 04/20for Q1 | Hart Health Strategies | Under $5,000 |
| 04/20for Q1 | Hart Health Strategies | Under $5,000 |
| 01/20for Q4 2025 | Covington & Burling | $170K |
| 01/16for Q4 2025 | Hart Health Strategies | Under $5,000 |
| 25/10/20for Q3 2025 | Hart Health Strategies | Under $5,000 |
| 25/10/20for Q3 2025 | Covington & Burling | $130K |
| 25/07/21for Q2 2025 | Covington & Burling | $220K |
| 25/07/10for Q2 2025 | Hart Health Strategies | Under $5,000 |
| 25/04/21for Q1 2025 | Covington & Burling | $420K |
| 25/04/18for Q1 2025 | Hart Health Strategies | Under $5,000 |
| 25/04/18for Q1 2025 | Hart Health Strategies | Under $5,000 |
| 25/01/21for Q4 2024 | Covington & Burling | $200K |
| 25/01/05for Q4 2024 | Hart Health Strategies | Under $5,000 |
| 24/10/21for Q3 2024 | Covington & Burling | $290K |
| 24/10/10for Q3 2024 | Hart Health Strategies | Under $5,000 |
| 24/07/22for Q2 2024 | Covington & Burling | $300K |
| 24/07/21for Q2 2024 | Hart Health Strategies | Under $5,000 |